We are live on ! Find out more
GBT

Global Blood Therapeutics, Inc.
GBT

Delisted

GBT was delisted on the 4th of October, 2022.

Back to rankings

2 hedge funds and large institutions have $42.1K invested in Global Blood Therapeutics, Inc. in 2022 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 239 closing their positions.

New
Increased
Maintained
Reduced
Closed

99% less funds holding

Funds holding: 247 → 2 (-245)

100% less funds holding in top 10

Funds holding in top 10: 21 → 0 (-21)

100% less capital invested

Capital invested by funds: $4.73B → $42.1K (-$4.73B)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 239

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
2
Holders Change
-245
Holders Change %
-99.19%
% of All Funds
0.03%
Holding in Top 10
–
Holding in Top 10 Change
-21
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
1
Closed
239
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$428M
2
BlackRock
BlackRock
New York
-$323M
3
BBA
Baker Bros. Advisors
New York
-$254M
4
PCM
Pentwater Capital Management
Florida
-$218M
5
State Street
State Street
Massachusetts
-$162M
Name Holding Trade Value Shares
Change 		Change in
Stake
Ameriprise
126
Ameriprise
Minnesota
– -$2.86M -42,003 Closed
PAM
127
Panagora Asset Management
Massachusetts
– -$2.86M -42,001 Closed
State of New Jersey Common Pension Fund D
128
State of New Jersey Common Pension Fund D
New Jersey
– -$2.56M -37,665 Closed
Wellington Management Group
129
Wellington Management Group
Massachusetts
– -$2.52M -37,029 Closed
AA
130
ALPS Advisors
Colorado
– -$2.51M -36,829 Closed
BPGAM
131
BTG Pactual Global Asset Management
Bermuda
– -$2.5M -36,771 Closed
MIM
132
MetLife Investment Management
New Jersey
– -$2.3M -33,813 Closed
KC
133
Kellner Capital
New York
– -$2.26M -33,235 Closed
CSS
134
Cubist Systematic Strategies
Connecticut
– -$2.24M -32,834 Closed
AIG
135
American International Group
New York
– -$2.09M -30,664 Closed
VAM
136
Vazirani Asset Management
New York
– -$2.04M -30,000 Closed
EP
137
Edgestream Partners
New Jersey
– -$1.92M -28,226 Closed
GC
138
Guggenheim Capital
Illinois
– -$1.92M -28,129 Closed
Mirae Asset Global Investments
139
Mirae Asset Global Investments
South Korea
– -$1.92M -28,111 Closed
Mariner
140
Mariner
Kansas
– -$1.9M -27,904 Closed
WAM
141
Wolverine Asset Management
Illinois
– -$1.87M -27,431 Closed
CC
142
Centiva Capital
New York
– -$1.76M -25,900 Closed
VOYA Investment Management
143
VOYA Investment Management
Georgia
– -$1.68M -24,727 Closed
Manulife (Manufacturers Life Insurance)
144
Manulife (Manufacturers Life Insurance)
Ontario, Canada
– -$1.65M -24,276 Closed
DekaBank Deutsche Girozentrale
145
DekaBank Deutsche Girozentrale
Germany
– -$1.63M -24,250 Closed
AG
146
Algert Global
California
– -$1.46M -21,393 Closed
WG
147
Winton Group
United Kingdom
– -$1.4M -20,528 Closed
Teacher Retirement System of Texas
148
Teacher Retirement System of Texas
Texas
– -$1.38M -20,234 Closed
State Board of Administration of Florida Retirement System
149
State Board of Administration of Florida Retirement System
Florida
– -$1.37M -20,154 Closed
CM
150
Caption Management
Oklahoma
– -$1.29M -18,900 Closed
4 5
6
7 8

GBT Hedge Fund Activity: Q4 2022 in Review

2 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Global Blood Therapeutics, Inc. (GBT) for Q4 2022, worth a combined $42.1K — down 100% from $4.73B a quarter earlier.

Sellers outnumbered buyers: 239 funds closed out of GBT and 0 opened new positions — a net loss of 239 holders — while 1 trimmed existing stakes and 0 added.

The largest seller was Vanguard Group, exiting entirely with an estimated $428M sold.

  • 2 institutional investors held Global Blood Therapeutics, Inc. (GBT) as of Q4 2022, down from 247 in Q3 2022.
  • Funds reported $42.1K of Global Blood Therapeutics, Inc. stock for Q4 2022, down 100% quarter-over-quarter.
  • 0 funds opened new Global Blood Therapeutics, Inc. positions in Q4 2022 and 239 closed out, a net change of -239 holders.
  • The largest Global Blood Therapeutics, Inc. seller in Q4 2022 was Vanguard Group, an estimated $428M sold.

Based on aggregated 13F filings for Q4 2022.